Objective
to compare FFR guided PCI with CABG in patients with 3 vessel coronary artery disease (CAD)
Study
multicentre, randomised, non-inferiority clinical trial
Population
patients with 3 vessel CAD
Endpoints
the primary endpoint was the occurrence within 1 year of a major adverse cardiac or cerebrovascular event, defined as death from any cause, myocardial infarction, stroke, or repeat revascularisation
Conclusion
in patients with three-vessel coronary artery disease, FFR-guided PCI was not found to be non-inferior to CABG with respect to the incidence of a composite of death, myocardial infarction, stroke, or repeat revascularisation at 1 year
Fearon et al. N Engl J Med. 2022;386:128-37
